TNGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Tango Therapeutics Inc (TNGX) is not a strong buy at the moment for a beginner investor with a long-term focus. While the stock has shown significant revenue growth and bullish moving averages, the lack of strong trading signals, declining net income, and mixed analyst sentiment suggest waiting for further clarity or a better entry point.
The stock's moving averages are bullish (SMA_5 > SMA_20 > SMA_200), indicating an uptrend. However, the MACD is negative and expanding downward (-0.0216), and RSI is neutral at 60.538. The stock is trading near its resistance level (R1: 13.01), which may limit immediate upside potential.
Analysts have raised price targets recently, with Piper Sandler and B. Riley setting targets at $14, reflecting optimism about the company's potential.
Revenue growth of 363.61% YoY in Q3 2025 demonstrates strong top-line expansion.
Bullish moving averages suggest a positive price trend.
Net income dropped significantly (-154.46% YoY), and EPS declined by -148.15% YoY in Q3 2025, indicating profitability challenges.
Wolfe Research expressed concerns about the strength of the company's drug pipeline in pancreatic cancer.
No recent news or congress trading activity to act as a catalyst.
In Q3 2025, revenue increased by 363.61% YoY to $53.81M, but net income dropped by -154.46% YoY to $15.88M. EPS also declined by -148.15% YoY to $0.13. Gross margin remained stable at 100%.
Analysts have mixed views. Piper Sandler and B. Riley are optimistic, raising price targets to $14, while Wolfe Research has a neutral stance, citing weak signals for the company's drug in pancreatic cancer. Stifel initiated coverage with a Buy rating and a $15 price target, citing potential for its drug pipeline.
